Back to News
Market Impact: 0.2
MAIA Biotechnology Board Member, CEO Buy Shares Amid Phase 3 NSCLC Studies
Source: Nasdaq
Healthcare & BiotechInsider TransactionsManagement & Governance
MAIA Biotechnology disclosed insider purchases by board member Ramiro Guerrero and founder/CEO Vlad Vitoc, increasing their ownership stakes in the clinical-stage immune-oncology company. The buying signals management and board confidence, but the article provides no transaction values, share counts, clinical data, or operational updates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
MAIA0.45
More News
- ASML’s CEO is putting his paycheck on the line for employee morale. It could help retain talent that’s nearly impossible to replace
- ‘Like Kashmir’: How a toxic marble dump yard became a tourist spot in India
- Apple CEO says the company doesn’t ‘want to ship AI for AI’s sake’
- Swiss firms plan to expand China investments as trade deal deepens ties
- Citi explains what ’hawk’ and ’dove’ really mean as ECB faces leadership change
- Republic Bancorp EVP Jeff Starke sells $75,769 in stock